Prostate-specific membrane antigen (PSMA) is a suggested target for antibody-based therapy of prostate cancer, potentially involved in the regulation of cell migration. As heterogeneity may limit the applicability of targeted therapies, this study was undertaken to estimate the degree of heterogeneity of PSMA expression in prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
For heterogeneity analysis, a prostate cancer heterogeneity TMA containing samples from 10 different tumor blocks of 189 consecutive prostate cancers was used PSMA expression was analyzed by immunohistochemistry
PSMA expression was found in 97 6% of 1171 interpretable tissue spots including 260 (22 2%) with weak, 345 (29 5%) with moderate, and 538 (45 9%) with strong positivity On a patient level, a positive PSMA immunostaining was found in 172 of 173 analyzable patients (99 4%) with at least a weak staining reaction PSMA immunostaining was homogenously positive in 161 prostate cancers (93 6%), whereas heterogenous PSMA positivity was seen in 11 of 172 positive cases (6 4%) In these cases, heterogeneity was intrafocal in 8 cases (72 7%) and interfocal in 27 3% cases PSMA expression was completely absent in 1 patient
Given the high frequency and high homogeneity of PSMA expression in prostate cancer, we conclude that increased PSMA expression may occur early in prostate cancer development High homogeneity of PSMA expression is a strong argument for a high utility of PSMA as a prostate cancer drug target
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2015 Jul [Epub]
Maria C Tsourlakis, Franka Klein, Martina Kluth, Alexander Quaas, Markus Graefen, Alexander Haese, Ronald Simon, Guido Sauter, Thorsten Schlomm, Sarah Minner
*Institute of Pathology †Martini-Clinic, Prostate Cancer Center ‡Department of Urology, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany